BioHealth Innovation
If you are having trouble viewing this email, please click here

August 20, 2019


Emergent BioSolutions’ New President and CEO, Bob Kramer, joins Rich Bendis on BioTalk

Bob Kramer joins BioTalk to discuss his history with Emergent, his vision for the company, and Emergent’s commitment to the BioHealth Capital Region. Mr. Kramer serves as president and CEO and as a member of the Board of Directors. He was appointed as CEO and as director effective April 2019 and has served as president since March 2018. Mr. Kramer also served as chief operating officer from March 2018 to March 2019. Prior to this, Mr. Kramer served as executive vice president and chief financial officer from September 2012. Mr. Kramer first joined Emergent in 1999 as its CFO. From 1999 until his retirement in 2010, he held various executive positions with the last being president of Emergent Biodefense Operations Lansing. Mr. Kramer returned to the company in 2011 as the interim head of the biosciences division, and then as interim executive vice president, corporate services division. Prior to joining Emergent in 1999, Mr. Kramer held various financial management positions at Pharmacia Corporation, which subsequently merged with the Upjohn Company in 1995 and eventually became part of Pfizer Inc. Mr. Kramer serves on the board of the U.S. Chamber of Commerce. Mr. Kramer received an M.B.A. from Western Kentucky University and a B.S. in industrial management from Clemson University.

iTunes (, Google (, and TuneIn (

Read More

Floreo just raised millions to help children with autism through VR - Washington Business Journal

Floreo started raising capital earlier this year to get its product in the hands of more users.

Read More

Johns Hopkins scientists raise $137M megaround for a trio of spinouts looking to tackle Alzheimer’s, Parkinson’s and fibrosis – Endpoints News

A US/Ko re an hy brid biotech run by a group of sci en tists out of Johns Hop kins just scored a megaround of $137.1 mil lion, with plans to ad vance a slate of ex per i men tal drugs held at its 3 sub sidiary op er a tions.

Read More

IBBR Collaborates with Integrated BioTherapeutics to Advance a Novel Approach to Treating Infectious Disease

Institute for Bioscience and Biotechnology Research (IBBR) Fellow Dr. Daniel Nelson (Associate Professor, Department of Veterinary Medicine, University of Maryland, College Park) is working on an innovative approach to treating bacterial disease in collaboration with Dr. Rajan Adhikari, Assistant Director of Bacteriology at Integrated BioTherapeutics (IBT), and George Mason University's Dr. Ramin Hakami (Associate Professor, School of Systems Biology and National Center for Biodefense and Infectious Diseases). The group recently received a $3M Phase II STTR award from the National Institutes of Health that will fund advancement of their novel immunotherapeutic into non-human primates, as well as optimization of a cell line for biomanufacturing the drug.

Read More

George Washington University, Barings strike 8-figure deal for Giapreza - Washington Business Journal

George Washington University just sold a portion of its royalty rights for a drug developed in its school of medicine, scoring a game-changing cash infusion it plans to reinvest in research and commercialization.

Read More

Three Richmond-area startups join forces to improve health care

Three health care-related startups based in the Richmond area have merged their operations with the goal of providing better preventative and personalized medical diagnostics.

The merger brings together Salveo Diagnostics, ImmunArray and Nudge, in what leaders of the three businesses describe as a combination “greater than the sum of its parts.”

Read More

Virginia Bio Names John Newby CEO | Business Wire

Virginia Bio, the statewide non-profit trade association for the life science industry, today announces that John L. Newby II is named CEO, effective August 5, 2019.

Tweet this Newby will be leaving his current role as the Commissioner of the Virginia Department of Veterans Services (VDVS), where he leads an 850-member Agency located across 50 Virginia locations, delivering employment, education, benefits, behavioral health and long term health care services to Virginia’s Reservists, Guardsmen, transitioning service members and 725,000 veterans.

Read More

The Future Of Life Science And Tech Innovation Is In Clusters

With technological advancement occurring at an increasingly breakneck pace, it's natural the number of life science and technology innovation clusters is growing as well. These clusters result from the increasing recognition that innovators do not perform at their best in widely dispersed buildings. Instead, they gain most from highly specialized facilities and collaborative ecosystems that foster cross-fertilization of ideas.

Read More

Children's National Extends Deadline for $150K NICU Pitch Competition

Innovators and startup companies with devices designed to improve neonatal or NICU care now have a one-week extension until Aug. 19, 2019 to apply for the $150K "Make Your Medical Device Pitch for Kids!" competition funded by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI).

Read More

Johns Hopkins, United Therapeutics launch postdoctoral fellowship in computational medicine | Hub

Johns Hopkins University and biotech company United Therapeutics Corporation have teamed up to create a new postdoctoral fellowship in the emerging field of computational medicine.

Read More

TEDCO elects four new board execs amid internal reorganization - Baltimore Business Journal

The state-backed tech group is also in the midst of finding a new CEO to replace George Davis, who left in July.

Read More

Special Invitation from Kinexum to Targeting Metabesity 2019 in October in Washington, DC

Targeting Metabesity 2019, co-chaired by Kinexum Executive Chairman Zan Fleming and Stanford Professor Larry Steinman (a co-discoverer of Tysabri), will take place October 15-16, 2019, at the Carnegie Institution for Science in Washington, DC, see

Emerging science over the past couple decades suggests that many chronic diseases of aging (including diabetes, obesity, cardiovascular and neurodegenerative diseases, cancer and the aging process itself) have common metabolic roots, and thus may be susceptible to common solutions. We believe we are at a similar stage to the cusp of the moonshot, or the human genome project, where the science is accumulating, but alignment of policy and socioeconomic factors may be needed, in order to enable and facilitate the translation of such science into material, accessible gains in public health.

Read More

The ‘Dragon’ Targets U.S. Biopharma Lead

Perhaps the report on China’s strategy for eclipsing the U.S. lead in biopharma from the Information Technology & Innovation Foundation (ITIF) resonated so strongly with me because of several articles in The Wall Street Journal. Taken together, they present a sobering picture of what we’re up against.

Read More

Opportunity Zones: An EDA Priority

EDA is encouraging its economic development partners to think of Opportunity Zone investment as a new arrow in their quiver to not only enhance ROI for business interests, but also to encourage the public/private partnerships needed to drive private investment to distressed areas.

Read More

Top 10 Companies Leveraging Gene Editing in 2019

Bayer made much of its desire to establish a cell therapy pipeline on August 8 when it announced it would shell out up to $600 million to acquire full control of BlueRock Therapeutics. But the deal is just the latest example of growing interest by biopharma giants in applying gene editing toward new treatments.

Read More

Lilly Launches Innovation Challenge to Transform IBD Care Through Digital Health -

Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease (IBD) care. The challenge, “Transforming IBD Care: Better disease monitoring, management, and care for people with inflammatory bowel disease” focuses on innovation in IBD monitoring, condition management or care enhancements.

Read More

Venture capital investment in AI and mental health startups surges in Q2: report | FierceHealthcare

Investment in healthcare artificial intelligence startups and companies focused on mental health and wellness soared in the second quarter as both sectors hit funding highs, according to a new report.

Read More

Multiple Interferons, Including IFNB1, May Play a Role in SLE - The Rheumatologist

Through gene analysis, researchers have found different types of interferons in systemic lupus erythematosus (SLE) tissues and cells, such as skin and synovium. The analysis, which probed 2,000 gene expression datasets from SLE patients, specifically investigated modules of genes derived from the downstream interferon gene signature. It found enriched downstream interferon signatures that were predominately from IFNB1. These interferon signatures were higher when compared with the expression of downstream interferon signatures in kidneys with lupus nephritis, according to the study, published April 23 in Nature Communications Biology.1

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.